In an expansion of its previous moves to cut insulin prices, Sanofi will cap the price of each of its insulin products at $35 per month in the U.S. regardless of a patient's insurance status. The move ...

CMS’ Part D Senior Savings Model effectively increased insulin use while reducing out-of-pocket costs among Medicare beneficiaries, according to a RAND report published Sept. 22. The program also ...

A nonprofit in Cambridge, Massachusetts is aiming to make insulin more accessible for diabetes patients in the United States by selling vials of the drug at a fraction of the cost. According to WBZ-TV ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A nonprofit in Massachusetts has ...

The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance ...

Take control of your health before it’s too late. Detecting insulin resistance early can help you prevent diabetes, heart disease, and more. Start tracking your fasting insulin now and make lifestyle ...

The maker of a new category of small, wearable insulin patch pumps—designed to comfortably provide therapy to people with diabetes while they sleep—has raised $23.6 million in early venture capital to ...

A new treatment for type 1 diabetes is moving closer to reality. In late 2024, a 46-year-old Swedish man received 17 injections of a unique pancreatic cell cocktail. The cells, donated from a healthy ...

A medical device manufacturer has issued an urgent correction for select insulin pumps due to a possible error that could result in insulin not being delivered, the U ...

Insulin is rising in cost despite its necessity for survival for people with diabetes. Patent evergreening by insulin manufacturers hinders competition and keeps prices high. Congress should pass ...

A man with type 1 diabetes has become the first patient to produce his own insulin after receiving genetically engineered cell transplants, without needing drugs to prevent rejection. The case, ...

O'Reilly Automotive Inc. is suing major pharmacy benefit managers (PBMs) and insulin manufacturers, alleging collusion to inflate insulin prices. The lawsuit accuses CVS Caremark, Express Scripts, ...